Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Rhomboids are intramembrane serine proteases that cleave the transmembrane helices of substrate proteins, typically releasing luminal/extracellular domains from the membrane. They are conserved in all branches of life and there is a growing recognition of their association with a wide range of human diseases. Human rhomboids, for example, have been implicated in cancer, metabolic disease and neurodegeneration, while rhomboids in apicomplexan parasites appear to contribute to their invasion of host cells. Recent advances in our knowledge of the structure and the enzyme function of rhomboids, and increasing efforts to identify specific inhibitors, are beginning to provide important insight into the prospect of rhomboids becoming future therapeutic targets. This article is part of a Special Issue entitled: Proteolysis as a Regulatory Event in Pathophysiology edited by Stefan Rose-John.

Original publication

DOI

10.1016/j.bbamcr.2017.04.016

Type

Journal article

Journal

Biochim Biophys Acta

Publication Date

11/2017

Volume

1864

Pages

2200 - 2209

Keywords

Disease, Enzyme, Protease, Rhomboid, Structure, Humans, Metabolic Diseases, Molecular Targeted Therapy, Neoplasms, Nerve Degeneration, Phylogeny, Proteolysis, Serine Proteases, Substrate Specificity